

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number  
**WO 2004/075914 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/17, A61P 17/02** (74) Agent: HARPER, David, S.; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).

(21) International Application Number:

PCT/US2004/004999

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 20 February 2004 (20.02.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/448,954	21 February 2003 (21.02.2003)	US
60/512,211	17 October 2003 (17.10.2003)	US
60/530,306	16 December 2003 (16.12.2003)	US

(71) Applicant (for all designated States except US): **ARIZONA BOARD OF REGENTS [US/US]**; Office of Technology Collaboration and Licensing, Box 873511, Tempe, AZ 85287-3511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BROPHY, Colleen** [US/US]; 15301 North 109th Street, Scottsdale, AZ 85255 (US). **PANITCH, Alyssa** [US/US]; 3703 East Indigo Bay Court, Higley, AZ 85236 (US). **PARMITER, Catherine** [GB/US]; 4843 East McNeil #1, Phoenix, AZ 85044 (US). **FURNISH, Elizabeth** [US/US]; 135 W. Hu-Esta Drive, Tempe, AZ 85282 (US). **KOMALAVILAS, Padmini** [US/US]; 900 West Grove Parkway #1109, Tempe, AZ 85283 (US).


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR PROMOTING WOUND HEALING AND/OR REDUCING SCAR FORMATION



(57) Abstract: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.

PhosphoHSP20 peptide disrupts the actin cytoskeleton.

WO 2004/075914 A1

## METHODS FOR PROMOTING WOUND HEALING AND/OR REDUCING SCAR FORMATION

### 5 Cross Reference

This application claims priority to U.S. Provisional Patent Application Serial Nos. 60/448,954 filed February 21, 2003; 60/512,211 filed October 17, 2003; and 60/530,306 filed December 16, 2003, each of which is incorporated by reference herein in its entirety.

### 10 Field of Invention

This invention relates generally to methods for promoting wound healing and inhibiting scar formation.

### Statement of Government Rights

15 This work was supported by a VA Merit Review Award and NIH RO1 HL58027-01.

### Background of the Invention

The primary goal in the treatment of wounds is to achieve wound closure. Many 20 wounds routinely heal by a process which comprises six major components: i) inflammation, ii) fibroblast proliferation, iii) blood vessel proliferation, iv) connective tissue synthesis v) epithelialization, and vi) wound contraction. Wound healing is impaired when these components, either individually or as a whole, do not function properly. Thus, therapeutics that provide a benefit to any of these components provide a 25 benefit to the wound healing process.

During wound healing, cells, including fibroblasts, migrate into the wound area. These cells form stress fibers and focal adhesions that serve to help close the wound during the wound contraction step. While wound contraction is an essential component of wound healing, the development of scar contractures in tissues and organs disrupts 30 normal organ integrity and produces functional deformities. Limiting wound contraction during the wound healing process allows the surrounding tissue more time to regenerate and heal with reduced scarring. Thus, compounds that limit wound contraction can be used to reduce scar formation that accompanies wound healing.


It has recently been determined that cyclic nucleotide-dependent relaxation of vascular smooth muscle is associated with an increase in the phosphorylation of the small heat shock related protein 20 ("HSP20"). HSP20 is highly and constitutively expressed in muscle tissues and can be phosphorylated in vitro by cGMP-dependent protein kinase.

5 HSP20 has been shown to associate with actin and  $\alpha$ -actinin, a focal adhesion protein. Activation of cyclic nucleotide dependent signaling pathways also leads to a decrease in the association of HSP20 with  $\alpha$ -actinin, suggesting that HSP20 may lead to relaxation of vascular smooth muscle through a dynamic association with cytoskeletal proteins.

However, the role of HSP20 and peptides derived therefrom in modulation of  
10 wound healing and scar formation responses is not known.

### Summary of the Invention

The present invention provides methods to promote wound healing and/or reduce scar formation, comprising administering to an individual in need thereof an amount  
15 effective to promote wound healing and/or reduce scar formation of one or more polypeptides comprising a sequence according to general formula I:



wherein X1 is 0-14 amino acids of the sequence of heat shock protein 20 between residues 1 and 14 of **SEQ ID NO: 298**;

20 X2 is selected from the group consisting of S, T, Y, D, E, hydroxylysine, hydroxyproline, phosphoserine analogs, and phosphotyrosine analogs; and

25 X3 is selected from the group consisting of (a) 0-140 amino acids of heat shock protein 20 between residues 21 and 160 of **SEQ ID NO:298**; and (b) 0, 1, 2, or 3 amino acids of a sequence of genus Z1-Z2-Z3, wherein Z1 is selected from the group consisting of G and D;

Z2 is selected from the group consisting of L and K; and

Z3 is selected from the group consisting of S, T, and K.

### BRIEF DESCRIPTION OF THE DRAWINGS

30 **Figure 1:** PhosphoHSP20 peptide disrupts the actin cytoskeleton. 3T3 cells were cultured and treated as indicated on the graph (4). Monomer g-actin was biochemically quantitated using a DNase 1 inhibition assay. The level of g-actin in the cell extract that

caused 50% inhibition of DNase 1 was estimated from a standard actin curve that was determined using known amounts of actin. \* P < 0.05 compared to untreated cells.

5 **Figure 2:** FITC-phosphoHSP20 peptide disrupts focal adhesions. Results from the focal adhesion assay using interference reflective microscopy on 3T3 cells treated as described (4). Each condition was tested in triplicate, and an average of 250 cells per coverslip was counted. A cell was scored positive if it contained at least five focal adhesions. Hep I (peptide from thrombospondin 1) was used as a positive control. \* P<0.05 compared to untreated cells.

10

### Detailed Description of the Invention

All references cited are herein incorporated by reference in their entirety.

Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: *Molecular Cloning: A Laboratory Manual* (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in *Methods in Enzymology* (M.P. Deutshcer, ed., (1990) Academic Press, Inc.); *PCR Protocols: A Guide to Methods and Applications* (Innis, et al. 1990. Academic Press, San Diego, CA), *Culture of Animal Cells: A Manual of Basic Technique, 2<sup>nd</sup> Ed.* (R.I. Freshney. 1987. Liss, Inc. New York, NY), *Gene Transfer and Expression Protocols*, pp. 109-128, ed. E.J. Murray, The Humana Press Inc., Clifton, N.J.), and the Ambion 1998 Catalog (Ambion, Austin, TX).

20 The single letter designation for amino acids is used predominately herein. As is well known by one of skill in the art, such single letter designations are as follows:

25 A is alanine; C is cysteine; D is aspartic acid; E is glutamic acid; F is phenylalanine; G is glycine; H is histidine; I is isoleucine; K is lysine; L is leucine; M is methionine; N is asparagine; P is proline; Q is glutamine; R is arginine; S is serine; T is threonine; V is valine; W is tryptophan; and Y is tyrosine.

30 As used herein, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. For example, reference to a "polypeptide" means one or more polypeptides.

In one aspect, the present invention provides methods for promoting wound healing and/or reducing scar formation comprising administering to an individual in need

thereof an amount effective to promote wound healing and/or reduce scar formation of a polypeptide comprising or consisting of a sequence according general formula I:

X1-A(X2)APLP-X3

wherein X1 is 0-14 amino acids of the sequence of heat shock protein 20 between residues 1 and 14 of **SEQ ID NO: 298**;

X2 is selected from the group consisting of S, T, Y, D, E, hydroxylysine, hydroxyproline, phosphoserine analogs, and phosphotyrosine analogs; and

X3 is selected from the group consisting of (a) 0-140 amino acids of residues 21 and 160 of **SEQ ID NO:298**; and (b) 0, 1, 2, or 3 amino acids of a sequence of genus Z1-Z2-Z3, wherein Z1 is selected from the group consisting of G and D;

Z2 is selected from the group consisting of L and K; and

Z3 is selected from the group consisting of S, T, and K.

Residues 15-21 from HSP20, with possible substitutions at residue 16 of HSP20 form the structural core of the polypeptides according to general formula I (A(X2)APLP) (**SEQ ID NO: 2**). The full sequence of HSP20 is provided as SEQ ID NO: 298, and is shown below:

*Met Glu Ile Pro Val Pro Val Gln Pro Ser Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Ser Ala Pro Gly Arg Leu Phe Asp Gln Arg Phe Gly Glu Gly Leu Leu Glu Ala Glu Leu Ala Ala Leu Cys Pro Thr Thr Leu Ala Pro Tyr Tyr Leu Arg Ala Pro Ser Val Ala Leu Pro Val Ala Gln Val Pro Thr Asp Pro Gly His Phe Ser Val Leu Leu Asp Val Lys His Phe Ser Pro Glu Glu Ile Ala Val Lys Val Val Gly Glu His Val Glu Val His Ala Arg His Glu Glu Arg Pro Asp Glu His Gly Phe Val Ala Arg Glu Phe His Arg Arg Tyr Arg Leu Pro Pro Gly Val Asp Pro Ala Ala Val Thr Ser Ala Leu Ser Pro Glu Gly Val Leu Ser Ile Gln Ala Ala Pro Ala Ser Ala Gln Ala Pro Pro Pro Ala Ala Ala Lys.*

The underlined residues represent amino acids 15-21.

X1 is 0-14 amino acids of SEQ ID NO: 298 between residues 1 and 14 of **SEQ ID NO:298** (shown in italics above). Thus, if X1 is 5 amino acids of residues 1 and 14 of **SEQ ID NO:298**, then X1 would be the 5 amino acids contiguous to residues 15-21, eg: SWLRR (**SEQ ID NO:303**). Similarly, where X1 is the following number of amino acids of residues 1-14 of **SEQ ID NO:298**, its identity is as shown below:

1 amino acid of **SEQ ID NO:298**: R

2 amino acids of **SEQ ID NO:298:** RR  
3 amino acids of **SEQ ID NO:298:** LRR (**SEQ ID NO: 304**)  
4 amino acids of **SEQ ID NO:298:** WLRR (**SEQ ID NO: 1**)  
6 amino acids of **SEQ ID NO:298:** PSWLRR (**SEQ ID NO: 305**)  
5 7 amino acids of **SEQ ID NO:298:** NPSWLRR (**SEQ ID NO: 306**)  
8 amino acids of **SEQ ID NO:298:** VNPSWLRR (**SEQ ID NO: 307**)  
9 amino acids of **SEQ ID NO:298:** PVNPSWLRR (**SEQ ID NO: 308**)  
10 10 amino acids of **SEQ ID NO:298:** VPVNPSWLRR (**SEQ ID NO: 309**)  
11 11 amino acids of **SEQ ID NO:298:** PVPVNPSWLRR (**SEQ ID NO: 310**)  
10 12 amino acids of **SEQ ID NO:298:** IPVPPVNPSWLRR (**SEQ ID NO: 311**)  
13 13 amino acids of **SEQ ID NO:298:** EIPVPPVNPSWLRR (**SEQ ID NO: 312**)  
14 14 amino acids of **SEQ ID NO:298:** MEIPVPPVNPSWLRR (**SEQ ID NO: 313**)

In a further embodiment, X1 is 0, 1, 2, 3, or 4 amino acids of the sequence WLRR  
15 (**SEQ ID NO:1**).

In one embodiment, X3 is 0-140 amino acids between residues 21 and 160 of **SEQ ID NO:298**. According to this embodiment, X3 can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 20 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139  
25 or 140 amino acids between residues 21 and 160 of **SEQ ID NO:298**.

For example, if X3 is 5 amino acids between residues 21 and 160 of **SEQ ID NO:298**, then X3 would be the 5 amino acids contiguous to residues 15-21, eg: GLSAP (**SEQ ID NO: 314**). Other possible X3 sequences will be apparent to one of skill in the art based on the teachings provided herein.

30 In another embodiment, X3 is 0, 1, 2, or 3 amino acids of a sequence of genus Z1-Z2-Z3, wherein Z1 is selected from the group consisting of G and D; Z2 is selected from the group consisting of L and K; and Z3 is selected from the group consisting of S, T, and K.

For example, if X3 is 2 amino acids of a sequence of the genus Z1-Z2-Z3, then the possibilities for X3 are GL, GK, DL, and DK. Other possible X3 sequences in this embodiment will be apparent to one of skill in the art based on the teachings provided herein.

5 According to various embodiments of the polypeptides of general formula I, X2 is S, T, Y, D E, a phosphoserine mimic, or a phosphotyrosine mimic. It is preferred that X2 is S, T, or Y; more preferred that X2 is S or T, and most preferred that X2 is S. In these embodiments where X2 is S, T, or Y, it is most preferred that X2 is phosphorylated. When X2 is D or E, these residues have a negative charge that mimics the phosphorylated state. The polypeptides of general formula I are optimally effective in the methods of the invention when X2 is phosphorylated, is a phosphoserine or phosphotyrosine mimic, or is another mimic of a phosphorylated amino acid residue, such as a D or E residue. Examples of phosphoserine mimics include, but are not limited to, sulfoserine, amino acid mimics containing a methylene substitution for the phosphate oxygen, 4-phosphono(difluoromethyl)phenylalanine, and L-2-amino-4-(phosphono)-4,4-difluorobutanoic acid. Other phosphoserine mimics can be made by those of skill in the art. Examples of phosphotyrosine mimics include, but are not limited to, phosphonomethylphenylalanine, difluorophosphonomethylphenylalanine, fluoro-O-malonyltyrosine and O-malonyltyrosine.

10 15 20

In a preferred embodiment, the polypeptide according to the general formula comprises or consists of an amino acid sequence according to SEQ ID NO:300 (WLRRApSAPLPGL), wherein the "pS" represents a phosphorylated serine residue.

In another embodiment, the polypeptides according to general formula I may further comprise one or more molecules comprising an aromatic ring. In one such embodiment, the one or molecules comprising an aromatic ring are amino acids, such as any combination of 1-5 phenylalanine (F), tyrosine (Y), or tryptophan (W) residues. Thus, for example, the polypeptides according to general formula I can further comprise any combination of F, Y, and W, such as F, FF, Y, YY, W, WW, FY, FW, YF, YW, WY, WF, or a 3, 4, or 5 amino acid combination of F, Y, and W. In another embodiment, the molecule comprising an aromatic ring is one or more molecules comprising one or more aromatic rings that can optionally be substituted with halogen, lower alkyl, lower alkylthio, trifluoromethyl, lower acyloxy, aryl, and heteroaryl. For example, the one or more molecules comprising one or more aromatic ring may comprise 9-fluorenylmethyl

25 30

(Fm). Examples of such molecules include, but are not limited to 9-fluorenylmethylcarbonyl, 9-fluorenylmethylcarbamates, 9-fluorenylmethylcarbonates, 9-fluorenylmethyl esters, 9-fluorenylmethylphosphates, and S-9-fluorenylmethyl thioethers. In embodiments wherein the molecule comprising an aromatic ring is not an amino acid, 5 it can be attached to the polypeptide by methods known in the art, including but not limited to, standard Fmoc protection chemistry employed in peptide synthesis.

Thus, according to these various embodiments, a representative sample of polypeptides according to general formula I for use in the methods of the invention include, but are not limited to, polypeptides comprising or consisting of the following 10 sequences: (ASAPLP) (SEQ ID NO:3); (ATAPLP) (SEQ ID NO:4); (RASAPLP) (SEQ ID NO:5); (RATAPLP) (SEQ ID NO:6); (AYAPLP) (SEQ ID NO:7); (RAYAPLP) (SEQ ID NO:8); (RRASAPLP) (SEQ ID NO:9); (LRRASAPLP) (SEQ ID NO:10); (WLRRASAPLP); (SEQ ID NO:11) (RRATAPLP) (SEQ ID NO:12); (LRRATAPLP) (SEQ ID NO:13); (WLRRATAPLP) (SEQ ID NO:14); (RAYAPLP) 15 (SEQ ID NO:15); (LRRAYAPLP) (SEQ ID NO:16); (WLRRAYAPLP) (SEQ ID NO:17); (RRASAPLPG) (SEQ ID NO:18); (RRASAPLPD) (SEQ ID NO:19); (RRASAPLPGL) (SEQ ID NO:20); (RRASAPLPKG) (SEQ ID NO:21); (RRASAPLPDL) (SEQ ID NO:22); (RRASAPLPDK) (SEQ ID NO:23); (RRASAPLPGLS) (SEQ ID NO:24); (RRASAPLPGLT) (SEQ ID NO:25); 20 (RRASAPLPGKS) (SEQ ID NO:26); (RRASAPLPGKT) (SEQ ID NO:27); (RRASAPLPDLS) (SEQ ID NO:28); (RRASAPLPDLT) (SEQ ID NO:29); (RRASAPLPDKS) (SEQ ID NO:30); (RRASAPLPDKT) (SEQ ID NO:31); (LRRASAPLPG) (SEQ ID NO:32); (LRRASAPLPD) (SEQ ID NO:33); (LRRASAPLPGL) (SEQ ID NO:34); (LRRASAPLPKG) (SEQ ID NO:35); 25 (LRRASAPLPDL) (SEQ ID NO:36); (LRRASAPLPDK) (SEQ ID NO:37); (LRRASAPLPGLS) (SEQ ID NO:38); (LRRASAPLPGLT) (SEQ ID NO:39); (LRRASAPLPGKS) (SEQ ID NO:40); (LRRASAPLPGKT) (SEQ ID NO:41); (LRRASAPLPDLS) (SEQ ID NO:42); (LRRASAPLPDLT) (SEQ ID NO:43); (LRRASAPLPDKS) (SEQ ID NO:44); (LRRASAPLPDKT) (SEQ ID NO:45); 30 (WLRRASAPLPG) (SEQ ID NO:46); (WLRRASAPLPD) (SEQ ID NO:47); (WLRRASAPLPGL) (SEQ ID NO:48); (WLRRASAPLPKG) (SEQ ID NO:49); (WLRRASAPLPDL) (SEQ ID NO:50); (WLRRASAPLPDK) (SEQ ID NO:51); (WLRRASAPLPGLS) (SEQ ID NO:52); (WLRRASAPLPGLT) (SEQ ID NO:53);

(WLRRASAPLPGKS) (SEQ ID NO:54); (WLRRASAPLPGKT) (SEQ ID NO:55);  
(WLRRASAPLPDLS) (SEQ ID NO:56); (WLRRASAPLPDLT) (SEQ ID NO:57);  
(WLRRASAPLPDKS) (SEQ ID NO:58); (WLRRASAPLPDKT) (SEQ ID NO:59);  
(RRATAPLPG) (SEQ ID NO:60); (RRATAPLPD) (SEQ ID NO:61); (RRATAPLPGL)  
5 (SEQ ID NO:62); (RRATAPLPGK) (SEQ ID NO:63); (RRATAPLPDL) (SEQ ID  
NO:64); (RRATAPLPDK) (SEQ ID NO:65); (RRATAPLPGLS) (SEQ ID NO:66);  
(RRATAPLPGLT) (SEQ ID NO:67); (RRATAPLPGKS) (SEQ ID NO:68);  
(RRATAPLPGKT) (SEQ ID NO:69); (RRATAPLPDLS) (SEQ ID NO:70);  
(RRATAPLPDLT) (SEQ ID NO:71); (RRATAPLPDKS) (SEQ ID NO:72);  
10 (RRATAPLPDKT) (SEQ ID NO:73); (LRRATAPLPG) (SEQ ID NO:74);  
(LRRATAPLPD) (SEQ ID NO:75); (LRRATAPLPGL) (SEQ ID NO:76);  
(LRRATAPLPGK) (SEQ ID NO:77); (LRRATAPLPDL) (SEQ ID NO:78);  
(LRRATAPLPDK) (SEQ ID NO:79); (LRRATAPLPGLS) (SEQ ID NO:80);  
(LRRATAPLPGLT) (SEQ ID NO:81); (LRRATAPLPGKS) (SEQ ID NO:82);  
15 (LRRATAPLPGKT) (SEQ ID NO:83); (LRRATAPLPDL) (SEQ ID NO:84);  
(LRRATAPLPDLT) (SEQ ID NO:85); (LRRATAPLPDKS) (SEQ ID NO:86);  
(LRRATAPLPDKT) (SEQ ID NO:87); (WLRRATAPLPG) (SEQ ID NO:88);  
(WLRRATAPLPD) (SEQ ID NO:89); (WLRRATAPLPGL) (SEQ ID NO:90);  
(WLRRATAPLPGK) (SEQ ID NO:91); (WLRRATAPLPDL) (SEQ ID NO:92);  
20 (WLRRATAPLPDK) (SEQ ID NO:93); (WLRRATAPLPGLS) (SEQ ID NO:94);  
(WLRRATAPLPGLT) (SEQ ID NO:95); (WLRRATAPLPGKS) (SEQ ID NO:96);  
(WLRRATAPLPGKT) (SEQ ID NO:97); (WLRRATAPLPDL) (SEQ ID NO:98);  
(WLRRATAPLPDLT) (SEQ ID NO:99); (WLRRATAPLPDKS) (SEQ ID NO:100);  
(WLRRATAPLPDKT) (SEQ ID NO:101); (RRAYAPLPG) (SEQ ID NO:102);  
25 (RRAYAPLPD) (SEQ ID NO:103); (RRAYAPLPGL) (SEQ ID NO:104);  
(RRAYAPLPGK) (SEQ ID NO:105); (RRAYAPLPDL) (SEQ ID NO:106);  
(RRAYAPLPDK) (SEQ ID NO:107); (RRAYAPLPGLS) (SEQ ID NO:108);  
(RRAYAPLPGLT) (SEQ ID NO:109); (RRAYAPLPGKS) (SEQ ID NO:110);  
(RRAYAPLPGKT) (SEQ ID NO:111); (RRAYAPLPDL) (SEQ ID NO:112);  
30 (RRAYAPLPDLT) (SEQ ID NO:113); (RRAYAPLPDKS) (SEQ ID NO:114);  
(RRAYAPLPDKT) (SEQ ID NO:115); (LRRAYAPLPG) (SEQ ID NO:116);  
(LRRAYAPLPD) (SEQ ID NO:117); (LRRAYAPLPGL) (SEQ ID NO:118);  
(LRRAYAPLPGK) (SEQ ID NO:119); (LRRAYAPLPDL) (SEQ ID NO:120);

(LRRAYAPLPDK) (SEQ ID NO:121); (LRRAYAPLPGLS) (SEQ ID NO:122); (LRRAYAPLPGLT) (SEQ ID NO:123); (LRRAYAPLPGKS) (SEQ ID NO:124); (LRRAYAPLPGKT) (SEQ ID NO:125); (LRRAYAPLPDLS) (SEQ ID NO:126); (LRRAYAPLPDLT) (SEQ ID NO:127); (LRRAYAPLPDKS) (SEQ ID NO:128); 5 (LRRAYAPLPDKT) (SEQ ID NO:129); (WLRRAYAPLPG) (SEQ ID NO:130); (WLRRAYAPLPD) (SEQ ID NO:131); (WLRRAYAPLPGL) (SEQ ID NO:132); (WLRRAYAPLPGK) (SEQ ID NO:133); (WLRRAYAPLPDL) (SEQ ID NO:134); (WLRRAYAPLPDK) (SEQ ID NO:135); (WLRRAYAPLPGLS) (SEQ ID NO:136); (WLRRAYAPLPGLT) (SEQ ID NO:137); (WLRRAYAPLPGKS) (SEQ ID NO:138); 10 (WLRRAYAPLPGKT) (SEQ ID NO:139); (WLRRAYAPLPDLS) (SEQ ID NO:140); (WLRRAYAPLPDLT) (SEQ ID NO:141); (WLRRAYAPLPDKS) (SEQ ID NO:142); and (WLRRAYAPLPDKT) (SEQ ID NO:143); ((F/Y/W)RRASAPLP) (SEQ ID NO:144); ((F/Y/W)LRRASAPLP) (SEQ ID NO:145); ((F/Y/W)WLRRASAPLP); (SEQ ID NO:146) ((F/Y/W)RRATAPLP) (SEQ ID NO:147); ((F/Y/W)LRRATAPLP) 15 (SEQ ID NO:148); ((F/Y/W)WLRRATAPLP) (SEQ ID NO:149); ((F/Y/W)RRAYAPLP) (SEQ ID NO:150); ((F/Y/W)LRRAYAPLP) (SEQ ID NO:151); ((F/Y/W)WLRRAYAPLP) (SEQ ID NO:152); ((F/Y/W)RRASAPLPG) (SEQ ID NO:153); ((F/Y/W)RRASAPLPD) (SEQ ID NO:154); ((F/Y/W)RRASAPLPGL) (SEQ ID NO:155); ((F/Y/W)RRASAPLPGK) (SEQ ID NO:156); ((F/Y/W)RRASAPLPDL) 20 (SEQ ID NO:157); ((F/Y/W)RRASAPLPDK) (SEQ ID NO:158); ((F/Y/W)RRASAPLPGLS) (SEQ ID NO:159); ((F/Y/W)RRASAPLPGLT) (SEQ ID NO:160); ((F/Y/W)RRASAPLPGKS); (SEQ ID NO:161); ((F/Y/W)RRASAPLPGKT) (SEQ ID NO:162); ((F/Y/W)RRASAPLPDLS) (SEQ ID NO:163); ((F/Y/W)RRASAPLPDLT) (SEQ ID NO:164); ((F/Y/W)RRASAPLPDKS) (SEQ ID 25 NO:165); ((F/Y/W)RRASAPLPDKT) (SEQ ID NO:166); ((F/Y/W)LRRASAPLPG) (SEQ ID NO:167); ((F/Y/W)LRRASAPLPD) (SEQ ID NO:168); ((F/Y/W)LRRASAPLPGL) (SEQ ID NO:169); ((F/Y/W)LRRASAPLPGK) (SEQ ID NO:170); ((F/Y/W)LRRASAPLPDL) (SEQ ID NO:171); ((F/Y/W)LRRASAPLPDK) (SEQ ID NO:172); ((F/Y/W)LRRASAPLPGLS) (SEQ ID NO:173); 30 ((F/Y/W)LRRASAPLPGLT) (SEQ ID NO:174); ((F/Y/W)LRRASAPLPGKS) (SEQ ID NO:175); ((F/Y/W)LRRASAPLPGKT) (SEQ ID NO:176); ((F/Y/W)LRRASAPLPDLS) (SEQ ID NO:177); ((F/Y/W)LRRASAPLPDLT) (SEQ ID NO:178); ((F/Y/W)LRRASAPLPDKS) (SEQ ID NO:179); ((F/Y/W)LRRASAPLPDKT) (SEQ ID

NO:180); ((F/Y/W)WLRRASAPLPG) (SEQ ID NO:181); ((F/Y/W)WLRRASAPLPD)  
(SEQ ID NO:182); ((F/Y/W)WLRRASAPLPGL) (SEQ ID NO:183);  
((F/Y/W)WLRRASAPLPGK) (SEQ ID NO:184); ((F/Y/W)WLRRASAPLPDL) (SEQ  
ID NO:185); ((F/Y/W)WLRRASAPLPDK) (SEQ ID NO:186);  
5 ((F/Y/W)WLRRASAPLPGLS) (SEQ ID NO:187); ((F/Y/W)WLRRASAPLPGLT)  
(SEQ ID NO:188); ((F/Y/W)WLRRASAPLPGKS) (SEQ ID NO:189);  
((F/Y/W)WLRRASAPLPGKT) (SEQ ID NO:190); ((F/Y/W)WLRRASAPLPDLS)  
(SEQ ID NO:191); ((F/Y/W)WLRRASAPLPDLT) (SEQ ID NO:192);  
((F/Y/W)WLRRASAPLPDKS) (SEQ ID NO:193); ((F/Y/W)WLRRASAPLPDKT)  
10 (SEQ ID NO:194); ((F/Y/W)RRATAPLPG) (SEQ ID NO:195);  
((F/Y/W)RRATAPLPD) (SEQ ID NO:196); ((F/Y/W)RRATAPLPGL) (SEQ ID  
NO:197); ((F/Y/W)RRATAPLPGK) (SEQ ID NO:198); ((F/Y/W)RRATAPLPDL)  
(SEQ ID NO:199); ((F/Y/W)RRATAPLPDK) (SEQ ID NO:200);  
((F/Y/W)RRATAPLPGLS) (SEQ ID NO:201); ((F/Y/W)RRATAPLPGLT) (SEQ ID  
15 NO:202); ((F/Y/W)RRATAPLPGKS) (SEQ ID NO:203); ((F/Y/W)RRATAPLPGKT)  
(SEQ ID NO:204); ((F/Y/W)RRATAPLPDLS) (SEQ ID NO:205);  
((F/Y/W)RRATAPLPDLT) (SEQ ID NO:206); ((F/Y/W)RRATAPLPDKS) (SEQ ID  
NO:207); ((F/Y/W)RRATAPLPDKT) (SEQ ID NO:208); ((F/Y/W)LRRATAPLPG)  
(SEQ ID NO:209); ((F/Y/W)LRRATAPLPD) (SEQ ID NO:210);  
20 ((F/Y/W)LRRATAPLPGL) (SEQ ID NO:211); ((F/Y/W)LRRATAPLPGK) (SEQ ID  
NO:212); ((F/Y/W)LRRATAPLPDL) (SEQ ID NO:213); ((F/Y/W)LRRATAPLPDK)  
(SEQ ID NO:214); ((F/Y/W)LRRATAPLPGLS) (SEQ ID NO:215);  
((F/Y/W)LRRATAPLPGLT) (SEQ ID NO:216); ((F/Y/W)LRRATAPLPGKS) (SEQ ID  
NO:217); ((F/Y/W)LRRATAPLPGKT) (SEQ ID NO:218);  
25 ((F/Y/W)LRRATAPLPDLS) (SEQ ID NO:219); ((F/Y/W)LRRATAPLPDLT) (SEQ ID  
NO:220); ((F/Y/W)LRRATAPLPDKS) (SEQ ID NO:221);  
((F/Y/W)LRRATAPLPDKT) (SEQ ID NO:222); ((F/Y/W)WLRRATAPLPG) (SEQ ID  
NO:223); ((F/Y/W)WLRRATAPLPD) (SEQ ID NO:224);  
((F/Y/W)WLRRATAPLPGL) (SEQ ID NO:225); ((F/Y/W)WLRRATAPLPGK) (SEQ  
30 ID NO:226); ((F/Y/W)WLRRATAPLPDL) (SEQ ID NO:227);  
((F/Y/W)WLRRATAPLPDK) (SEQ ID NO:228); ((F/Y/W)WLRRATAPLPGLS) (SEQ  
ID NO:229); ((F/Y/W)WLRRATAPLPGLT) (SEQ ID NO:230);  
((F/Y/W)WLRRATAPLPGKS) (SEQ ID NO:231); ((F/Y/W)WLRRATAPLPGKT)

(SEQ ID NO:232); ((F/Y/W)WLRRATAPLPDLS) (SEQ ID NO:233); ((F/Y/W)WLRRATAPLPDLT) (SEQ ID NO:234); ((F/Y/W)WLRRATAPLPDKS) (SEQ ID NO:235); ((F/Y/W)WLRRATAPLPDKT) (SEQ ID NO:236); ((F/Y/W)RRAYAPLPG) (SEQ ID NO:237); ((F/Y/W)RRAYAPLPD) (SEQ ID NO:238); ((F/Y/W)RRAYAPLPGL) (SEQ ID NO:239); ((F/Y/W)RRAYAPLPGLK) (SEQ ID NO:240); ((F/Y/W)RRAYAPLPDL) (SEQ ID NO:241); ((F/Y/W)RRAYAPLPDK) (SEQ ID NO:242); ((F/Y/W)RRAYAPLPGLS) (SEQ ID NO:243); ((F/Y/W)RRAYAPLPGLT) (SEQ ID NO:244); ((F/Y/W)RRAYAPLPGKS) (SEQ ID NO:245); ((F/Y/W)RRAYAPLPGKT) (SEQ ID NO:246); (F/Y/W)RRAYAPLPDLS) (SEQ ID NO:247); ((F/Y/W)RRAYAPLPDLT) (SEQ ID NO:248); ((F/Y/W)RRAYAPLPDKS) (SEQ ID NO:249); ((F/Y/W)RRAYAPLPDKT) (SEQ ID NO:250); ((F/Y/W)LRRAYAPLPG) (SEQ ID NO:251); ((F/Y/W)LRRAYAPLPD) (SEQ ID NO:252); ((F/Y/W)LRRAYAPLPGL) (SEQ ID NO:253); ((F/Y/W)LRRAYAPLPGLK) (SEQ ID NO:254); ((F/Y/W)LRRAYAPLPDL) (SEQ ID NO:255); ((F/Y/W)LRRAYAPLPDK) (SEQ ID NO:256); ((F/Y/W)LRRAYAPLPGLS) (SEQ ID NO:257); ((F/Y/W)LRRAYAPLPGLT) (SEQ ID NO:258); ((F/Y/W)LRRAYAPLPGKS) (SEQ ID NO:259); ((F/Y/W)LRRAYAPLPGKT) (SEQ ID NO:260); ((F/Y/W)LRRAYAPLPDLS) (SEQ ID NO:261); ((F/Y/W)LRRAYAPLPDLT) (SEQ ID NO:262); ((F/Y/W)LRRAYAPLPDKS) (SEQ ID NO:263); ((F/Y/W)LRRAYAPLPDKT) (SEQ ID NO:264); ((F/Y/W)WLRRAYAPLPG) (SEQ ID NO:265); ((F/Y/W)WLRRAYAPLPD) (SEQ ID NO:266); ((F/Y/W)WLRRAYAPLPGL) (SEQ ID NO:267); ((F/Y/W)WLRRAYAPLPGLK) (SEQ ID NO:268); ((F/Y/W)WLRRAYAPLPDL) (SEQ ID NO:269); ((F/Y/W)WLRRAYAPLPDK) (SEQ ID NO:270); ((F/Y/W)WLRRAYAPLPGLS) (SEQ ID NO:271); ((F/Y/W)WLRRAYAPLPGLT) (SEQ ID NO:272); ((F/Y/W)WLRRAYAPLPGKS) (SEQ ID NO:273); ((F/Y/W)WLRRAYAPLPGKT) (SEQ ID NO:274); ((F/Y/W)WLRRAYAPLPDLS) (SEQ ID NO:275); ((F/Y/W)WLRRAYAPLPDLT) (SEQ ID NO:276); ((F/Y/W)WLRRAYAPLPDKS) (SEQ ID NO:277); and ((F/Y/W)WLRRAYAPLPDKT) (SEQ ID NO:278) wherein (F/Y/W) means that the residue is selected from F, Y, and W. Other specific polypeptides falling within the scope of general formula I will be readily apparent to one of skill in the art based on the teachings herein.

The polypeptides of general formula I may be present in multiple copies to provide increased efficacy for use in the methods of the invention. For example, the polypeptides may be present in 1, 2, 3, 4, or 5 copies. In a further embodiment, the polypeptides comprising a sequence according to general formula I comprise a 5 combination of different sequences from the region X1-A(X2)APLP-X3. In this embodiment, for example, the polypeptide can consist of 1 copy of SEQ ID NO: 9 and 1 copy of SEQ ID NO: 143. In a different example, the polypeptide could consist of 2 copies of SEQID NO: 200 and 3 copies of SEQ ID NO: 62. It will be apparent to one of skill in the art that many such combinations are possible based on the teachings of the 10 present invention.

In a preferred embodiment, the polypeptides according to general formula I further comprise one or more transduction domains. As used herein, the term “transduction domain” means an amino acid sequence that can carry the polypeptide across cell membranes. These domains can be linked to other polypeptides to direct 15 movement of the linked polypeptide across cell membranes. In some cases the transducing molecules do not need to be covalently linked to the active polypeptide. In a preferred embodiment, the transduction domain is linked to the rest of the polypeptide via peptide bonding. Examples of such transduction domains include, but are not limited to (R)<sub>4-9</sub> (SEQ ID NO:279); GRKKRRQRRPPQ (SEQ ID NO:280); YARAAARQARA 20 (SEQ ID NO:281); DAATATRGRSAASRPTERPRAPARSASRPRRPVE (SEQ ID NO:282); GWTLNSAGYLLGLINLKALAALAKKIL (SEQ ID NO:283); PLSSIFSRIGDP (SEQ ID NO:284); AAVALLPAVLLALLAP (SEQ ID NO:285); AAVLLPVLLAAP (SEQ ID NO:286); VTVLALGALAGVGVG (SEQ ID NO:287); GALFLGWLGAGSTMGAWSQP (SEQ ID NO:288); 25 GWTLNSAGYLLGLINLKALAALAKKIL (SEQ ID NO:289); KLALKLALKALKAAALKLA (SEQ ID NO:290); KETWWETWWTEWSQPKKKRKV (SEQ ID NO:291); KAFAKLAARLYRKAGC (SEQ ID NO:292); KAFAKLAARLYRAAGC (SEQ ID NO:293); AAFAKLAARLYRKAGC (SEQ ID NO:294); KAFAALAARLYRKAGC (SEQ ID NO:295); KAFAKLAAQLYRKAGC 30 (SEQ ID NO:296), GGGGYGRKKRRQRR (SEQ ID NO:297), and YGRKKRRQRR (SEQ ID NO:299).

In a further embodiment, the polypeptides comprise or consist of polypeptides of the formula:

B1-X1-A(X2)APLP-X3-B2

wherein X1, X2, and X3 are as defined above, and wherein B1 and B2 are 5 independently absent or comprise a transduction domain, as described above.

In a preferred embodiment, one or both of B1 and B2 comprise or consist of the amino acid sequence of YGRKKRRQRRR (SEQ ID NO:299) and/or YARAAARQARA (SEQ ID NO:281). In a most preferred embodiment, the polypeptide according to the general formulas disclosed herein comprises or consists of a polypeptide 10 according to YGRKKRRQRRWLRRApSAPLPGL (SEQ ID NO:301) or YARAAARQARAWLRRApSAPLPGL (SEQ ID NO:315), wherein "pS" represents a phosphorylated serine residue.

In a further embodiment of the methods of the present invention, the polypeptides comprise or consist of polypeptides of the formula:

15 J1-J2-X1-A(X2)APLP-X3-J3

wherein X1, X2, and X3 are as defined above, wherein J2 and J3 are independently absent or comprise a transduction domain, as described above, and wherein J1 is absent or is one or more molecules comprising one or more aromatic ring, as discussed above.

20 The polypeptides for use in the methods of the invention can further be derivatized to provide enhanced half-life, for example, by linking to polyethylene glycol. The polypeptides of the invention may comprise L-amino acids, D-amino acids (which are resistant to L-amino acid-specific proteases *in vivo*), a combination of D- and L-amino acids, and various "designer" amino acids (e.g.,  $\beta$ -methyl amino acids,  $\text{C}\alpha$ -methyl 25 amino acids, and  $\text{N}\alpha$ -methyl amino acids, etc.) to convey special properties. Synthetic amino acids include ornithine for lysine, and norleucine for leucine or isoleucine.

30 In addition, the polypeptides can have peptidomimetic bonds, such as ester bonds, to prepare polypeptides with novel properties. For example, a peptide may be generated that incorporates a reduced peptide bond, i.e.,  $\text{R}_1\text{-CH}_2\text{-NH-R}_2$ , where  $\text{R}_1$  and  $\text{R}_2$  are amino acid residues or sequences. A reduced peptide bond may be introduced as a dipeptide subunit. Such polypeptides are resistant to protease activity, and possess an extended half-life *in vivo*.

The term "polypeptide" is used in its broadest sense to refer to a sequence of subunit amino acids, amino acid analogs, or peptidomimetics. The subunits are linked by peptide bonds, although the polypeptide can comprise further moieties that are not necessarily linked to the polypeptide by a peptide bond. For example, as discussed 5 above, the polypeptide can further comprise a non-amino acid molecule that contains an aromatic ring.

The polypeptides described herein may be chemically synthesized or recombinantly expressed. Recombinant expression can be accomplished using standard methods in the art, generally involving the cloning of nucleic acid sequences capable of 10 directing the expression of the polypeptides into an expression vector, which can be used to transfect or transduce a host cell in order to provide the cellular machinery to carry out expression of the polypeptides. Such expression vectors can comprise bacterial or viral expression vectors, and such host cells can be prokaryotic or eukaryotic.

Preferably, the polypeptides for use in the methods of the present invention are 15 chemically synthesized. Synthetic polypeptides, prepared using the well-known techniques of solid phase, liquid phase, or peptide condensation techniques, or any combination thereof, can include natural and unnatural amino acids. Amino acids used for peptide synthesis may be standard Boc (N $\alpha$ -amino protected N $\alpha$ -t-butyloxycarbonyl) amino acid resin with the standard deprotecting, neutralization, coupling and wash 20 protocols of standard solid phase procedure, or base-labile N $\alpha$ -amino protected 9-fluorenylmethoxycarbonyl (Fmoc) amino acids. Both Fmoc and Boc N $\alpha$ -amino protected amino acids can be obtained from Sigma, Cambridge Research Biochemical, or other chemical companies familiar to those skilled in the art. In addition, the polypeptides can be synthesized with other N $\alpha$ -protecting groups that are familiar to those skilled in this 25 art.

Solid phase peptide synthesis may be accomplished by techniques familiar to those in the art and provided, for example by using automated synthesizers.

As used herein, an "individual in need thereof" is an individual that has suffered or will suffer (for example, via a surgical procedure) a wound that may result in scar 30 formation, or has resulted in scar formation. As used herein, the term "wound" refers broadly to injuries to the skin and subcutaneous tissue, but does not include wounds to blood vessels or heart tissue.

Such wounds include, but are not limited to lacerations; burns; punctures; pressure sores; bed sores; canker sores; trauma, bites; fistulas; ulcers; lesions caused by infections; periodontal wounds; endodontic wounds; burning mouth syndrome; laparotomy wounds; surgical wounds; incisional wounds; contractures after burns; tissue fibrosis, including 5 but not limited to idiopathic pulmonary fibrosis, hepatic fibrosis, renal fibrosis, retroperitoneal fibrosis, and cystic fibrosis, but excluding blood vessel fibrosis or heart tissue fibrosis; and wounds resulting from cosmetic surgical procedures. As used herein, the phrase "reducing scar formation" means any decrease in scar formation that provides a therapeutic or cosmetic benefit to the patient. Such a therapeutic or 10 cosmetic benefit can be achieved, for example, by decreasing the size and/or depth of a scar relative to scar formation in the absence of treatment with the methods of the invention, or by reducing the size of an existing scar.

As used herein, such scars include scars of all types, including but not limited to keloids; hypertrophic scars; and adhesion formation between organ surfaces, including 15 but not limited to those occurring as a result of surgery.

The present invention, by providing methods for reducing scar formation, will be clinically useful for treating all types of wounds to reduce scar formation, both for reducing initial scar formation, and for therapeutic treatment of existing scars (i.e.: cutting out the scar after its formation, treating it with the compounds of the invention, and 20 letting the scar heal more slowly). Such wounds are as described above. As used herein, the phrase "promoting wound healing" means any increase in wound healing that provides a therapeutic or cosmetic benefit to the patient. Such a therapeutic benefit can be achieved, for example, by one or more of increasing the rate of wound healing and/or increasing the degree of wound healing relative to an untreated individual. Such wounds 25 are as described above.

In a preferred embodiment, the individual is a mammal; in a more preferred embodiment, the individual is a human.

While not being limited to a specific mechanism of action, the inventors believe that the beneficial effect of the methods of the invention in promoting wound healing 30 and/or reducing scar formation are due to reduction of wound contraction within the wound area, which limits scar formation that accompanies wound healing, and increase in blood flow to the wound area.

As used herein, an "amount effective" of the one or more polypeptides is an amount that is sufficient to provide the intended benefit of treatment. An effective amount of the polypeptides that can be employed ranges generally between about 0.01  $\mu\text{g}/\text{kg}$  body weight and about 10  $\text{mg}/\text{kg}$  body weight, preferably ranging between about 5 0.05  $\mu\text{g}/\text{kg}$  and about 5  $\text{mg}/\text{kg}$  body weight. However dosage levels are based on a variety of factors, including the type of injury, the age, weight, sex, medical condition of the individual, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely by a physician using standard methods.

10 The polypeptides may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

For administration, the polypeptides are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be 15 admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidone, dextran sulfate, heparin-containing gels, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be 20 dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other 25 materials well known in the art.

The polypeptides or pharmaceutical compositions thereof may be administered by any suitable route, including orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, 30 intravenous, intra-arterial, intramuscular, intrasternal, intratendinous, intraspinal, intracranial, intrathoracic, infusion techniques or intraperitoneally. Preferred embodiments for administration vary with respect to the condition being treated. In a preferred embodiment, the polypeptides or pharmaceutical compositions are disposed on or

in a wound dressing or other topical administration. Such wound dressings can be any used in the art, including but not limited to films (e.g., polyurethane films), hydrocolloids (hydrophilic colloidal particles bound to polyurethane foam), hydrogels (cross-linked polymers containing about at least 60% water), foams (hydrophilic or hydrophobic), 5 calcium alginates (nonwoven composites of fibers from calcium alginate), cellophane, and biological polymers such as those described in US patent application publication number 20030190364, published October 9, 2003.

The polypeptides may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The 10 polypeptides of the invention may be applied in a variety of solutions. Suitable solutions for use in accordance with the invention are sterile, dissolve sufficient amounts of the polypeptides, and are not harmful for the proposed application.

15 **Example 1** Actin cytoskeleton disruption

**Materials and Methods**

**Peptide synthesis and purification**

Peptides were synthesized using standard f-moc chemistry and purified using high performance liquid chromatography (HPLC) by Cell Essentials (Boston, MA). 20 Fluorescent peptides were synthesized with a fluorescein isothiocyanate (FITC) labeled on the N terminus, using  $\beta$ -alanine as a linker.

**Cell culture, immunocytochemistry, and interference reflection microscopy**

Unless otherwise stated, all reagents were purchased from Sigma, St. Louis, MO. 25 Swiss Albino 3T3 fibroblasts (ATCC, Manassas, VA) were cultured in DMEM supplemented with 10% BCS, 4 mM L-glutamine and 50  $\mu$ g/ml penicillin-streptomycin and maintained at 37°C, 5% CO<sub>2</sub>. Cells were seeded and cultured overnight. Culture media was replaced with DMEM containing 0.5% BCS 1 hour prior to experimentation. Cells were incubated with the peptide analogues or 30 reagent (LPA or forskolin) diluted in DMEM containing 0.5% BCS, 30 minutes at 37°C. Cells were then fixed in 4% paraformaldehyde, permeabilized in 0.25% Triton X-100, and blocked with 1% BSA solution for 1 hour. To determine f-actin cytoskeletal distribution, treated cells were incubated with Alexa 568 phalloidin

(Molecular Probes, Eugene, OR) in 1% BSA, 30 minutes. To determine focal adhesion protein localization, treated cells were incubated with primary monoclonal antibodies for  $\alpha$ -actinin (1:100, Upstate, Charlottesville, VA), vinculin (1:100, Sigma) or paxillin (1:100, BD Bioscience-Transduction Labs, San Jose, CA) in 1% BSA solution for 2 hours, rinsed in PBS and incubated 60 min with Cy3-goat IgG secondary antibody (Jackson ImmunoResearch, West Grove, PA). Slides were mounted and analyzed by confocal microscopy (Leica TCS SP2, Bannockburn, IL). Interference reflection microscopy was used to determine the percentage of 3T3 cells positive for focal adhesions. Cells were cultured as described above and either untreated or treated with 100 nM Hep I (thrombospondin peptide), 10  $\mu$ M and 25  $\mu$ M pHSP20 (phospho HSP20 peptide) or 10  $\mu$ M and 25  $\mu$ M sHSP20 (scrambled HSP20 peptide).

## Results

15 Cellular processes such as cell adhesion, cytokinesis, cell motility, migration, and muscular contraction/relaxation require dynamic reorganization of the actin cytoskeleton. Activation of cyclic nucleotide signaling pathways in various cell types leads to profound alterations in the cytoskeleton, which include loss of central stress fibers and focal adhesion plaques; cytoplasmic retraction with the formation of thin processes; and 20 rounding of the cell bodies (1). In aggregate, these changes lead to a star-shaped appearance that has been termed "stellation."

The cyclic nucleotide signaling pathways include adenylate cyclase/cAMP/cAMP-dependent protein kinase (PKA) and guanylate cyclase/cGMP/cGMP-dependent protein kinase (PKG). These pathways converge at the 25 phosphorylation of the small heat shock-related protein, HSP20 on serine 16 (2, 3). To determine if HSP20 mediates cyclic nucleotide-dependent stellation, phosphopeptide analogues of HSP20 (pHSP20) were synthesized (4) that contained: 1) the amino acid sequence surrounding the phosphorylation site of HSP20 (WLRRApSAPLPGL) (SEQ ID NO:300); 2) a phosphoserine (pS); and 3) an 11 amino acid protein transduction domain 30 from the HIV Tat protein (YGRKKRRQRRR). The sequence of the resulting test polypeptide is YGRKKRRQRRRWLRRApSAPLPGL (SEQ ID NO:301). Control peptides contained the same sequence as the phosphopeptide analogues except with either

an alanine in place of the phosphoserine (aHSP20) or a scrambled HSP20 sequence containing phosphoserine (scrHSP20, PRpSLWALGRPLSAK) (SEQ ID NO:302).

Swiss albino 3T3 cells were either untreated or treated with 10  $\mu$ M LPA, 10  $\mu$ M forskolin, 25  $\mu$ M FITC-pHSP20, or 25  $\mu$ M FITC-aHSP20 as described (4). Cells were 5 fixed, stained for f-actin using Alexa 568 phalloidin, and visualized by projection images of confocal fluorescence microscopy. FITC-peptide fluorescence was overlayed with actin staining to show colocalization. Cells that had been exposed to serum (10%) or lysophosphatidic acid (10  $\mu$ M, 30 min) displayed robust stress fibers. Cells that were treated with the adenylate cyclase activator forskolin (10  $\mu$ M, 30 min) or with pHSP20 10 displayed stellate morphology and disrupted stress fibers. Cells that were treated with the control peptide aHSP20 did not lead to alterations in morphology or stress fibers.

To confirm that the loss of stress fibers is associated with loss of filamentous (f-) actin and commensurate increases in globular (g-) actin, a DNase 1 inhibition assay was 15 performed (5). 3T3 cells were cultured and treated as indicated (4). Monomer g-actin was biochemically quantitated using a DNase 1 inhibition assay. The level of g-actin in the cell extract that caused 50% inhibition of DNase 1 was estimated from a standard actin curve that was determined using known amounts of actin. Forskolin (10  $\mu$ M, 30 min) and pHSP20 (25  $\mu$ M, 30 min) treatment led to increases in g-actin (Fig. 1). Thus, 20 transduction of pHSP20 led to similar changes in actin filament dynamics and cellular morphology, as did activation of the upstream adenylate cyclase activator forskolin.

To further verify disruption of the actin cytoskeletal network upon addition of pHSP20, the presence of focal adhesions was examined by interference reflection microscopy (6, 7). Focal adhesions are plaque-like scaffolds of both structural and signaling proteins that link the cytoskeleton to the extracellular matrix through integrin 25 and syndecan receptors. Focal adhesions are formed in response to cell adhesion and involve signaling through Rho. These are dynamic structures that undergo disassembly and restructuring, characterized by loss of stress fibers and dispersion of vinculin,  $\alpha$ -actinin, and paxillin, and are associated with increased cell motility. The matricellular proteins thrombospondin and tenascin-C cause focal adhesion disassembly and 30 introduction of the intermediate cell adhesive state in a manner that requires basal PKG activity (7).

Swiss albino 3T3 cells were either untreated, or treated for 30 min with 10  $\mu$ M LPA, 10  $\mu$ M forskolin, 25  $\mu$ M pHSP20, 25  $\mu$ M FITC-aHSP20, and immunostained for  $\alpha$ -actinin, vinculin, or paxillin. Confocal projection images for FITC-peptides were overlayed with actin staining to show colocalization (f, i). Scale bar 50  $\mu$ m.

5 Cells treated with forskolin or pHSP20 displayed a decrease in focal adhesion accumulations of  $\alpha$ -actinin, vinculin, and paxillin, while cells treated with aHSP20 appeared to retain focal adhesion proteins. The pHSP20 led to disruption of focal adhesions in cultured 3T3 cells similar to the loss of focal adhesions that occurred with the heptapeptide of thrombospondin (Fig. 2), which has been shown to signal focal adhesion disassembly in a PKG-dependent manner (7). Again, aHSP20 had no effect on 10 focal adhesions. These data suggest that phosphorylated HSP20 might be one of the downstream effectors by which PKG mediates focal adhesion disruption. These experiments further suggest that HSP20 and functionally equivalent polypeptides thereof, are useful for promoting wound healing and/or reducing scar formation.

15

#### REFERENCES FOR EXAMPLE 1

1. G. J. Ramakers, W. H. Moolenaar, *Exp. Cell Res.* **245**, 252 (1998).
2. A. Beall *et al.*, *J. Biol. Chem.* **274**, 11344 (1999).
3. C. R. Flynn *et al.*, *Faseb J.* **17**, 1358 (2003).
- 20 4. Materials and methods are available as supporting material on *Science Online*.
5. C. S. Heacock, J. R. Bamburg, *Anal. Biochem.* **135**, 22 (1983).
6. J. E. Murphy-Ullrich, S. Gurusiddappa, W. A. Frazier, M. Hook, *J. Biol. Chem.* **268**, 26784 (1993).
7. J. E. Murphy-Ullrich *et al.*, *J. Cell. Sci.* **109**, 2499 (1996).

25

#### Example 2: Enhancing neural electrode durability

The durability of neural recording electrodes depends on scar formation. The scar formation in neural tissue is referred to as gliosis or glial scarring and results in insulation of the electrode from the neuronal tissues. These electrodes are often implanted into the 30 brain for long-term monitoring of neuronal population activities for investigation of motor control or stimulation for treatment of neural trauma or diseases. In order to achieve the full potential of neural recording electrodes, methods must be developed to

reduce scar formation and improve the interface between the electrode and the electrically active neurons. The reduction of scar formation will improve both short- and long-term recording potential of the electrodes. Modulation of scar tissue formation around neural electrodes will improve function of stimulating electrodes as will including deep brain 5 electrodes for Parkinson's disease, cochlear implants, and spinal cord stimulators. Since scar tissue acts as an insulator, improved conduction of action potentials to the electrodes will improve the performance of all implanted neural electrodes.

**Neural Recording electrodes:** Electrodes, when implanted into the brain, become encapsulated over time. Two biological responses result in encapsulation. The first 10 involves the formation of a compact barrier of fibroblasts and extracellular matrix around the electrode. The second, gliosis, involves the glial cells of the brain. Gliosis is characterized by phenotypic modulation of astrocytes into glial cells, which produce extracellular matrix and further promote scar formation. There is a correlation between tissue trauma and degree of capsule formation with thicker capsules being formed in areas 15 of higher tissue trauma. The increased trauma leads to disruption of the blood-brain barrier, which in turn, introduces blood-borne molecules into the brain. Glial scars, or capsules, can be up to 250  $\mu\text{m}$  thick. These capsules act as insulators, impeding the conduction of electrical signals from neurons to the recording electrodes, thus limiting the function of the electrodes.

20 Inhibiting astrocyte proliferation and extracellular matrix formation around the site of electrodes will increase both the longevity and strength of the recording signals. Upon exposure to blood-borne factors, astrocytes exhibit morphological changes, which include stress fiber formation and loss of stellation. Stellation is a term used to describe 25 alterations to the actin cytoskeleton that result in cells adopting a star-like or stellate shape. Upon loss of stellate morphology, astrocytes proliferate and secrete extracellular matrix proteins, which forms glial scars. Lysophosphatidic acid, a lipid found in high concentrations in blood, has been associated with the loss of stellate morphology, astrocytes proliferation, and gliosis.

30 Lysophosphatidic acid (LPA) is a biologically active signaling molecule that is bound to serum albumin in the blood. LPA can reverse stellation in astrocytes; this is likely due to inhibition of the cAMP pathway. LPA also can cause neurite retraction. HSP20 is the substrate molecule of both the cAMP and cGMP pathways and that its phosphorylation at serine 16 results in disruption of actin filaments.

Microwire arrays were implanted in the motor cortex of Sprague Dawley rats. Six male Sprague-Dawley rats (300-450g) were implanted with 2x4 arrays of 50 $\mu$ m tungsten wire. The electrodes were spaced 500 um apart for a total array size of approximately 1.5mm x 0.5mm. The implant was centered +3mm anterior and +2mm lateral from bregma. The craniotomy was opened slightly larger than the implant size and an injection (0.1 cc, 0.9 % PBS or 100  $\mu$ m p20) was made into the arachnoid space near the implant site using a 30 gauge needle. The mirowire array was held in a micromanipulator and lowered 2mm from the surface of the dura. The craniotomy was covered with Gelfoam® and the implant and connector were cemented in place with dental acrylic. Three groups were implanted and evaluated histologically after four weeks. Group one was implanted with untreated electrodes. Group two was implanted with dextran coated microwire electrodes and group three was implanted with dextran coated electrodes and received a subdural injection of the HSP20 biomimetic peptide (YGRKKRRQRRWLRApSAPLPGL (SEQ ID NO:301). At 4 weeks two animals from each group were sacrificed for histology. Animals were anesthetized and perfused with PBS followed by formalin. The brain tissue was dissected from the skull and sectioned into 100  $\mu$ M sections using a vibrotome. Sections were permeablized with 0.05% triton and blocked with bovine serum albumin followed by probing with rabbit anti-glial fibrillary acidic protein (GFAP) for astrocytes and goat anti-microtubule associated protein 2 (MAP2) for axons. Texas Red labeled anti-Rabbit and Cy5 labeled anti-j-donkey secondary antibodies were used respectively for visualization.

While significant glial scarring was seen with neural electrodes alone at four weeks, reduced scarring was seen with dextran coated electrodes. For the electrodes implanted with the addition of the HSP20 biomimetic peptide, essentially no scarring was observed; in addition, a higher density of axons was seen in the vicinity of the microwire electrodes. This data suggests that the HSP20 peptide is effective at both inhibiting scarring around the electrodes and enhancing axon survival in the vicinity of the implant, and further suggest that HSP20 and functionally equivalent polypeptides thereof are useful for promoting wound healing and/or reducing scar formation.

**We claim:**

1. A method for reducing scar formation, comprising administering to an individual in need thereof an amount effective to reduce scar formation of a polypeptide comprising  
5 a sequence according general formula I:

X1-A(X2)APLP-X3

wherein X1 is 0-14 amino acids of the sequence of heat shock protein 20 between residues 1 and 14 of SEQ ID NO: 298;

10 X2 is selected from the group consisting of S, T, Y, D, E, hydroxylysine, hydroxyproline, phosphoserine analogs and phosphotyrosine analogs; and  
X3 is selected from the group consisting of (a) 0-140 amino acids of heat shock protein 20 between residues 21 and 160 of SEQ ID NO:298; and (b) 0, 1, 2, or 3 amino acids of a sequence of genus Z1-Z2-Z3, wherein Z1 is selected from the group consisting of G and D;  
15 Z2 is selected from the group consisting of L and K; and  
Z3 is selected from the group consisting of S, T, and K.

20 2. The method of claim 1 wherein X1 is 0-14 amino acids of the sequence of heat shock protein 20 between residues 1 and 14 of SEQ ID NO: 298.

25 3. The method of claim 1 wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:298.

4. The method of claim 1 wherein X2 is selected from the group consisting of S, T, and Y, and wherein X2 is phosphorylated.

25 5. The method of claim 4 wherein X2 is S.

30 6. The method of claim 1 wherein the polypeptide comprises a sequence according to SEQ ID NO:300.

7. The method of claim 1 wherein the polypeptide comprises a polypeptide of the formula:

**B1-X1-A(X2)APLP-X3-B2**

wherein X1, X2, and X3 are as defined above, and wherein B1 and B2 are independently absent or comprise a transduction domain, as described above.

5 8. The method of claim 7 wherein one or both of B1 and B2 comprises the amino acid sequence of SEQ ID NO:299 and/or SEQ ID NO:281.

9. The method of claim 1 wherein the polypeptide comprises a polypeptide of SEQ ID NO:301 or SEQ ID NO:315.

10

10. The method of claim 1 wherein the polypeptide comprises a polypeptide of the formula::

**J1-J2-X1-A(X2)APLP-X3-J3**

15 wherein X1, X2, and X3 are as defined above, wherein J2 and J3 are independently absent or comprise a transduction domain, and wherein J1 is absent or is one or more molecules comprising one or more aromatic ring.

11. The method of claim 1 wherein the individual in need thereof has a wound selected from the group consisting of lacerations; burns; punctures; pressure sores; bed sores; canker sores; trauma, bites; fistulas; ulcers; lesions caused by infections; periodontal wounds; endodontic wounds; burning mouth syndrome; laparotomy wounds; surgical wounds; incisional wounds; contractures after burns; tissue fibrosis; and wounds resulting from cosmetic surgical procedures

25 12. The method of claim 1 wherein the method is used for reducing initial scar formation.

13. A method for promoting wound healing, comprising administering to an individual in need thereof an amount effective to promote wound healing of a polypeptide comprising a sequence according general formula I:

30 **X1-A(X2)APLP-X3**

wherein X1 is 0-14 amino acids of the sequence of heat shock protein 20 between residues 1 and 14 of SEQ ID NO: 298;

X2 is selected from the group consisting of S, T, Y, D, E, hydroxylysine, hydroxyproline, phosphoserine analogs and phosphotyrosine analogs; and

X3 is selected from the group consisting of (a) 0-140 amino acids of heat shock protein 20 between residues 21 and 160 of SEQ ID NO:298; and (b) 0, 1, 2, or 3 amino

5 acids of a sequence of genus Z1-Z2-Z3, wherein Z1 is selected from the group consisting of G and D;

Z2 is selected from the group consisting of L and K; and

Z3 is selected from the group consisting of S, T, and K.

10 14. The method of claim 13 wherein X1 is 0-14 amino acids of the sequence of heat shock protein 20 between residues 1 and 14 of SEQ ID NO: 298.

15 15. The method of claim 13 wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:298.

15

16. The method of claim 13 wherein X2 is selected from the group consisting of S, T, and Y, and wherein X2 is phosphorylated.

17. The method of claim 16 wherein X2 is S.

20

18. The method of claim 13 wherein the polypeptide comprises a sequence according to SEQ ID NO:300.

25 19. The method of claim 13 wherein the polypeptide comprises a polypeptide of the formula:

B1-X1-A(X2)APLP-X3-B2

wherein X1, X2, and X3 are as defined above, and wherein B1 and B2 are independently absent or comprise a transduction domain, as described above.

30 20. The method of claim 19 wherein one or both of B1 and B2 comprises the amino acid sequence of SEQ ID NO:299 and/or SEQ ID NO:281.

21. The method of claim 13 wherein the polypeptide comprises a polypeptide of SEQ ID NO:301 or SEQ ID NO:315.

22. The method of claim 13 wherein the polypeptide comprises a polypeptide of the  
5 formula::


J1-J2-X1-A(X2)APLP-X3-J3

wherein X1, X2, and X3 are as defined above, wherein J2 and J3 are independently absent or comprise a transduction domain, and wherein J1 is absent or is one or more molecules comprising one or more aromatic ring.


10

23. The method of claim 13 wherein the individual in need thereof has a wound selected from the group consisting of lacerations; burns; punctures; pressure sores; bed sores; canker sores; trauma, bites; fistulas; ulcers; lesions caused by infections; periodontal wounds; endodontic wounds; burning mouth syndrome; laparotomy wounds; 15 surgical wounds; incisional wounds; contractures after burns; tissue fibrosis; and wounds resulting from cosmetic surgical procedures

20



**Figure 1:** PhosphoHSP20 peptide disrupts the actin cytoskeleton.



**Figure 2:** PhosphoHSP20 peptide disrupts focal adhesions.

03-228\_PCT.SeqListing1  
SEQUENCE LISTING

<110> Brophy, Colleen  
Panitch, Alyssa  
Parmiter, Catherine  
Furnish, Elizabeth  
Komalavilas, Padmini

<120> METHODS FOR PROMOTING WOUND HEALING AND REDUCING SCAR FORMATION

<130> 03-228-PCT

<150> US 60/448,954  
<151> 2003-02-21

<150> US 60/512,211  
<151> 2003-10-17

<150> US 60/530,306  
<151> 2003-12-16

<160> 315

<170> PatentIn version 3.1

<210> 1  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 1

Trp Leu Arg Arg  
1

<210> 2  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (2)..(3)  
<223> X stands for any amino acid residue

<400> 2

Ala Xaa Xaa Ala Pro Leu Pro  
1 5

<210> 3  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 3 03-228\_PCT.SeqListing1

Ala Ser Ala Pro Leu Pro  
1 5

<210> 4  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 4

Ala Thr Ala Pro Leu Pro  
1 5

<210> 5  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 5

Arg Ala Ser Ala Pro Leu Pro  
1 5

<210> 6  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 6

Arg Ala Thr Ala Pro Leu Pro  
1 5

<210> 7  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 7

Ala Tyr Ala Pro Leu Pro  
1 5

<210> 8  
<211> 7  
<212> PRT  
<213> Artificial Sequence

## 03-228\_PCT.SeqListing1

<220>  
<223> Derived sequence  
<400> 8  
  
Arg Ala Tyr Ala Pro Leu Pro  
1 5

<210> 9  
<211> 8  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 9

Arg Arg Ala Ser Ala Pro Leu Pro  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 10

Leu Arg Arg Ala Ser Ala Pro Leu Pro  
1 5

<210> 11  
<211> 10  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 11

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro  
1 5 10

<210> 12  
<211> 8  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 12

Arg Arg Ala Thr Ala Pro Leu Pro  
1 5

<210> 13  
<211> 9

## 03-228\_PCT.SeqListing1

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 13

Leu Arg Arg Ala Thr Ala Pro Leu Pro  
1 5

<210> 14  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 14

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro  
1 5 10

<210> 15  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 15

Arg Arg Ala Tyr Ala Pro Leu Pro  
1 5

<210> 16  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 16

Leu Arg Arg Ala Tyr Ala Pro Leu Pro  
1 5

<210> 17  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 17

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 18  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 18

Arg Arg Ala Ser Ala Pro Leu Pro Gly  
1 5

<210> 19  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 19

Arg Arg Ala Ser Ala Pro Leu Pro Asp  
1 5

<210> 20  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 20

Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 21  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 21

Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 22  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 22

03-228\_PCT.SeqListing1  
Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 23  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 23

Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 24  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 24

Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 25  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 25

Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 26  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 26

Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 27  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

## 03-228\_PCT.SeqListing1

&lt;400&gt; 27

Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Thr  
1 5 10

&lt;210&gt; 28

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 28

Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Ser  
1 5 10

&lt;210&gt; 29

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 29

Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Thr  
1 5 10

&lt;210&gt; 30

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 30

Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Ser  
1 5 10

&lt;210&gt; 31

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 31

Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Thr  
1 5 10

&lt;210&gt; 32

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

## 03-228\_PCT.SeqListing1

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 32

Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly  
1 5 10

&lt;210&gt; 33

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 33

Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp  
1 5 10

&lt;210&gt; 34

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 34

Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu  
1 5 10

&lt;210&gt; 35

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 35

Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys  
1 5 10

&lt;210&gt; 36

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 36

Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu  
1 5 10

&lt;210&gt; 37

## 03-228\_PCT.SeqListing1

<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 37

Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 38  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 38

Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 39  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 39

Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 40  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 40

Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 41  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 41

Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Thr  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 42  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 42

Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 43  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 43

Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 44  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 44

Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 45  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 45

Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 46  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 46

## 03-228\_PCT.SeqListing1

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly  
1 5 10

<210> 47  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 47

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp  
1 5 10

<210> 48  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 48

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 49  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 49

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 50  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 50

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 51  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>

## 03-228\_PCT.SeqListing1

&lt;223&gt; Derived sequence

&lt;400&gt; 51

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys  
1 5 10

&lt;210&gt; 52

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 52

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Ser  
1 5 10

&lt;210&gt; 53

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 53

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Thr  
1 5 10

&lt;210&gt; 54

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 54

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Ser  
1 5 10

&lt;210&gt; 55

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 55

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Thr  
1 5 10

&lt;210&gt; 56

&lt;211&gt; 13

&lt;212&gt; PRT

<213> Artificial Sequence 03-228\_PCT.SeqListing1

<220>

<223> Derived sequence

<400> 56

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 57

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<400> 57

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 58

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<400> 58

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 59

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<400> 59

Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 60

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<400> 60

Arg Arg Ala Thr Ala Pro Leu Pro Gly  
1 5

## 03-228\_PCT.SeqListing1

<210> 61  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
  
<400> 61

Arg Arg Ala Thr Ala Pro Leu Pro Asp  
1 5

<210> 62  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
  
<400> 62

Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 63  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
  
<400> 63

Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 64  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
  
<400> 64

Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 65  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
  
<400> 65

Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys

1 5 03-228\_PCT.SeqListing1  
10

<210> 66  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 66

Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 67  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 67

Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 68  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 68

Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 69  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 69

Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 70  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

## 03-228\_PCT.SeqListing1

&lt;400&gt; 70

Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

&lt;210&gt; 71

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 71

Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

&lt;210&gt; 72

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 72

Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

&lt;210&gt; 73

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 73

Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

&lt;210&gt; 74

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 74

Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly  
1 5 10

&lt;210&gt; 75

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

## 03-228\_PCT.SeqListing1

<220>  
<223> Derived sequence

<400> 75

Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp  
1 5 10

<210> 76  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 76

Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 77  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 77

Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 78  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 78

Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 79  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence  
<400> 79

Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 80  
<211> 12

## 03-228\_PCT.SeqListing1

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 80

Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 81

<211> 12

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 81

Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 82

<211> 12

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 82

Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 83

<211> 12

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 83

Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 84

<211> 12

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 84

Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 85  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 85

Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 86  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 86

Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 87  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 87

Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 88  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 88

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly  
1 5 10

<210> 89  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 89

## 03-228\_PCT.SeqListing1

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp  
1 5 10

<210> 90  
<211> 12  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Derived sequence  
  
<400> 90

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 91  
<211> 12  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Derived sequence  
  
<400> 91

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 92  
<211> 12  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Derived sequence  
  
<400> 92

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 93  
<211> 12  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Derived sequence  
  
<400> 93

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 94  
<211> 13  
<212> PRT  
<213> Artificial sequence  
  
<220>  
<223> Derived sequence

## 03-228\_PCT.SeqListing1

<400> 94

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 95

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<400> 95

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 96

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<400> 96

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 97

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<400> 97

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 98

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<400> 98

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 99

<211> 13

<212> PRT

<213> Artificial Sequence

## 03-228\_PCT.SeqListing1

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 99

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

&lt;210&gt; 100

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 100

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

&lt;210&gt; 101

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 101

Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

&lt;210&gt; 102

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 102

Arg Arg Ala Tyr Ala Pro Leu Pro Gly  
1 5

&lt;210&gt; 103

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 103

Arg Arg Ala Tyr Ala Pro Leu Pro Asp  
1 5

&lt;210&gt; 104

## 03-228\_PCT.SeqListing1

<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 104

Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 105  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 105

Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 106  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 106

Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 107  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 107

Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 108  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 108

Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

## 03-228\_PCT.seqListing1

<210> 109  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 109

Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 110  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 110

Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 111  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 111

Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 112  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 112

Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 113  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 113

## 03-228\_PCT.SeqListing1

Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 114  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 114

Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 115  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 115

Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 116  
<211> 10  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 116

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly  
1 5 10

<210> 117  
<211> 10  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 117

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp  
1 5 10

<210> 118  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>

## 03-228\_PCT.SeqListing1

&lt;223&gt; Derived sequence

&lt;400&gt; 118

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu  
1 5 10

&lt;210&gt; 119

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 119

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys  
1 5 10

&lt;210&gt; 120

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 120

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu  
1 5 10

&lt;210&gt; 121

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 121

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys  
1 5 10

&lt;210&gt; 122

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 122

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

&lt;210&gt; 123

&lt;211&gt; 12

&lt;212&gt; PRT

## 03-228\_PCT.SeqListing1

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 123

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

&lt;210&gt; 124

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 124

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

&lt;210&gt; 125

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 125

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

&lt;210&gt; 126

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 126

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

&lt;210&gt; 127

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 127

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 128  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 128

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Ser  
1 .5 10

<210> 129  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 129

Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 130  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 130

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly  
1 5 10

<210> 131  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 131

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp  
1 5 10

<210> 132  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 132

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu  
Page 28

1

5

03-228\_PCT.SeqListing1  
10

<210> 133  
<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 133

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 134  
<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 134

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 135  
<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 135

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 136  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 136

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 137  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence

## 03-228\_PCT.SeqListing1

&lt;400&gt; 137

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

&lt;210&gt; 138

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 138

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

&lt;210&gt; 139

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 139

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

&lt;210&gt; 140

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 140

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

&lt;210&gt; 141

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 141

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

&lt;210&gt; 142

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

## 03-228\_PCT.SeqListing1

<220>  
<223> Derived sequence

<400> 142

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 143  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence  
<400> 143

Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 144  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 144

Xaa Arg Arg Ala Ser Ala Pro Leu Pro  
1 5

<210> 145  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 145

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro  
1 5 10

<210> 146  
<211> 11  
<212> PRT  
<213> Artificial Sequence

## 03-228\_PCT.SeqListing1

<220>  
<223> Derived sequence  
  
<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 146

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro  
1 5 10

<210> 147  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 147

Xaa Arg Arg Ala Thr Ala Pro Leu Pro  
1 5

<210> 148  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 148

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro  
1 5 10

<210> 149  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)

<223> X stands for any of F, Y, or W. 03-228\_PCT.SeqListing1

<400> 149

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro  
1 5 10

<210> 150

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 150

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro  
1 5

<210> 151

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 151

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro  
1 5 10

<210> 152

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 152

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 153  
<211> 10  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 153

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Gly  
1 5 10

<210> 154  
<211> 10  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 154

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Asp  
1 5 10

<210> 155  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 155

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 156  
<211> 11  
<212> PRT  
<213> Artificial sequence

## 03-228\_PCT.SeqListing1

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 156

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 157  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 157

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 158  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 158

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 159  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

## 03-228\_PCT.SeqListing1

<400> 159

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 160

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 160

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 161

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 161

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 162

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 162

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Thr  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 163  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 163

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 164  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 164

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 165  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 165

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 166  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>

## 03-228\_PCT.SeqListing1

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 166

Xaa Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Thr  
1 5 10

&lt;210&gt; 167

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 167

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly  
1 5 10

&lt;210&gt; 168

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 168

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp  
1 5 10

&lt;210&gt; 169

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

## 03-228\_PCT.SeqListing1

<400> 169

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 170

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> Derived sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 170

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 171

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> Derived sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 171

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 172

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> Derived sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 172

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 173  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 173

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 174  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 174

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 175  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 175

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 176  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence

## 03-228\_PCT.SeqListing1

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 176

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 177  
<211> 13  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 177

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 178  
<211> 13  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 178

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 179  
<211> 13  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

## 03-228\_PCT.SeqListing1

&lt;400&gt; 179

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Ser  
1 5 10

&lt;210&gt; 180

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 180

Xaa Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Thr  
1 5 10

&lt;210&gt; 181

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 181

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly  
1 5 10

&lt;210&gt; 182

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 182

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp  
1 5 10

&lt;210&gt; 183

## 03-228\_PCT.SeqListing1

<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 183

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 184  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 184

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 185  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 185

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 186  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

## 03-228\_PCT.SeqListing1

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 186

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 187  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 187

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 188  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 188

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 189  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 189

## 03-228\_PCT.SeqListing1

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 190  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 190

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 191  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 191

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 192  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 192

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 193  
<211> 14

## 03-228\_PCT.SeqListing1

<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 193

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Ser  
1 . 5 10

<210> 194  
<211> 14  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 194

Xaa Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Asp Lys Thr  
1 . 5 10

<210> 195  
<211> 10  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 195

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Gly  
1 . 5 10

<210> 196  
<211> 10  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>

## 03-228\_PCT.SeqListing1

<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 196

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Asp  
1 5 10

<210> 197  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 197

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 198  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 198

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 199  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> 1X stands for any of F, Y, or W.

<400> 199

## 03-228\_PCT.SeqListing1

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 200  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 200

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 201  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 201

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 202  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 202

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 203  
<211> 12  
<212> PRT

<213> Artificial Sequence 03-228\_PCT.SeqListing1

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 203

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 204

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> misc\_feature

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 204

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 205

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> misc\_feature

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 205

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 206

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> misc\_feature

## 03-228\_PCT.SeqListing1

<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 206

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 207  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 207

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 208  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 208

Xaa Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 209  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 209

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly  
Page 50

1 5 10 03-228\_PCT.SeqListing1

<210> 210  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 210

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp  
1 5 10

<210> 211  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 211

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 212  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 212

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 213  
<211> 12  
<212> PRT  
<213> Artificial Sequence

## 03-228\_PCT.SeqListing1

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 213

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 214  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 214

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 215  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 215

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 216  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)

03-228\_PCT.SeqListing1

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 216

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

&lt;210&gt; 217

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 217

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

&lt;210&gt; 218

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 218

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

&lt;210&gt; 219

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 219

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 220  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 220

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 221  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 221

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 222  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 222

Xaa Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 223  
<211> 12  
<212> PRT  
<213> Artificial Sequence

## 03-228\_PCT.SeqListing1

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 223

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly  
1 5 10

<210> 224  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 224

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp  
1 5 10

<210> 225  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 225

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 226  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

## 03-228\_PCT.SeqListing1

<400> 226

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 227

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<223> Derived sequence

<220>

<221> misc\_feature

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 227

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 228

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<223> Derived sequence

<220>

<221> misc\_feature

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 228

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 229

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Derived sequence

<220>

<221> misc\_feature

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 229

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 230  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 230

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 231  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 231

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 232  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 232

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 233  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>

## 03-228\_PCT.SeqListing1

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 233

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

&lt;210&gt; 234

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 234

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

&lt;210&gt; 235

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 235

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

&lt;210&gt; 236

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

## 03-228\_PCT.SeqListing1

<400> 236

Xaa Trp Leu Arg Arg Ala Thr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 237

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> misc\_feature

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 237

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Gly  
1 5 10

<210> 238

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> misc\_feature

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 238

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Asp  
1 5 10

<210> 239

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<220>

<221> misc\_feature

<222> (1)..(1)

<223> X stands for any of F, Y, or W.

<400> 239

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu  
1 5 10

## 03-228\_PCT.SeqListing1

<210> 240  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 240

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 241  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 241

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 242  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 242

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 243  
<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence

## 03-228\_PCT.SeqListing1

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 243

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 244  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 244

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 245  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 245

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 246  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

## 03-228\_PCT.SeqListing1

&lt;400&gt; 246

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

&lt;210&gt; 247

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 247

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

&lt;210&gt; 248

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 248

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

&lt;210&gt; 249

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 249

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

&lt;210&gt; 250

## 03-228\_PCT.SeqListing1

<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 250

Xaa Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 251  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 251

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly  
1 5 10

<210> 252  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 252

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp  
1 5 10

<210> 253  
<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence

## 03-228\_PCT.SeqListing1

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 253

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 254  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 254

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 255  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 255

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 256  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 256

## 03-228\_PCT.SeqListing1

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys  
1 5 10

<210> 257  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 257

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

<210> 258  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 258

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

<210> 259  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 259

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 260  
<211> 13

## 03-228\_PCT.SeqListing1

<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 260

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 261  
<211> 13  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 261

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 262  
<211> 13  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 262

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Thr  
1 5 10

<210> 263  
<211> 13  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<220>

## 03-228\_PCT.SeqListing1

<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 263

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 264  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 264

Xaa Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 265  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 265

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly  
1 5 10

<210> 266  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 266

03-228\_PCT.SeqListing1  
Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp  
1 5 10

<210> 267  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 267

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 268  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 268

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys  
1 5 10

<210> 269  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 269

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu  
1 5 10

<210> 270  
<211> 13  
<212> PRT

## 03-228\_PCT.SeqListing1

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 270

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys  
1 5 10

&lt;210&gt; 271

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 271

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Ser  
1 5 10

&lt;210&gt; 272

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; X stands for any of F, Y, or W.

&lt;400&gt; 272

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Leu Thr  
1 5 10

&lt;210&gt; 273

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

## 03-228\_PCT.SeqListing1

<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 273

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Ser  
1 5 10

<210> 274  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 274

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Gly Lys Thr  
1 5 10

<210> 275  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 275

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Ser  
1 5 10

<210> 276  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 276

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Leu Thr  
Page 70

1 5 03-228\_PCT.SeqListing1  
10

<210> 277  
<211> 14  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 277

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Ser  
1 5 10

<210> 278  
<211> 14  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (1)..(1)  
<223> X stands for any of F, Y, or W.

<400> 278

Xaa Trp Leu Arg Arg Ala Tyr Ala Pro Leu Pro Asp Lys Thr  
1 5 10

<210> 279  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (5)..(9)  
<223> Residues 5 through 9 are optionally absent.

<400> 279

Arg Arg Arg Arg Arg Arg Arg Arg  
1 5

<210> 280  
<211> 13  
<212> PRT  
<213> Artificial Sequence

## 03-228\_PCT.SeqListing1

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 280

Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln  
1 5 10

&lt;210&gt; 281

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 281

Tyr Ala Arg Ala Ala Ala Arg Gln Ala Arg Ala  
1 5 10

&lt;210&gt; 282

&lt;211&gt; 34

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 282

Asp Ala Ala Thr Ala Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr  
1 5 10 15

Glu Arg Pro Arg Ala Pro Ala Arg Ser Ala Ser Arg Pro Arg Arg Pro  
20 25 30

Val Glu

&lt;210&gt; 283

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 283

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Leu Ile Asn Leu  
1 5 10 15

Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu  
20 25

&lt;210&gt; 284

&lt;211&gt; 12

&lt;212&gt; PRT

## 03-228\_PCT.SeqListing1

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 284

Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro  
1 5 10

&lt;210&gt; 285

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 285

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

&lt;210&gt; 286

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 286

Ala Ala Val Leu Leu Pro Val Leu Leu Ala Ala Pro  
1 5 10

&lt;210&gt; 287

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 287

Val Thr Val Leu Ala Leu Gly Ala Leu Ala Gly Val Gly Val Gly  
1 5 10 15

&lt;210&gt; 288

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Derived sequence

&lt;400&gt; 288

Gly Ala Leu Phe Leu Gly Trp Leu Gly Ala Ala Gly Ser Thr Met Gly  
1 5 10 15

Ala Trp Ser Gln Pro  
20

03-228\_PCT.SeqListing1

<210> 289  
<211> 27  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<400> 289

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Leu Ile Asn Leu  
1 5 10 15

Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu  
20 25

<210> 290  
<211> 18  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<400> 290

Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys  
1 5 10 15

Leu Ala

<210> 291  
<211> 21  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<400> 291

Lys Glu Thr Trp Trp Glu Thr Trp Trp Thr Glu Trp Ser Gln Pro Lys  
1 5 10 15

Lys Lys Arg Lys Val  
20

<210> 292  
<211> 16  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Derived sequence

<400> 292

## 03-228\_PCT.SeqListing1

Lys Ala Phe Ala Lys Leu Ala Ala Arg Leu Tyr Arg Lys Ala Gly Cys  
1 5 10 15

<210> 293  
<211> 16  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 293

Lys Ala Phe Ala Lys Leu Ala Ala Arg Leu Tyr Arg Ala Ala Gly Cys  
1 5 10 15

<210> 294  
<211> 16  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 294

Ala Ala Phe Ala Lys Leu Ala Ala Arg Leu Tyr Arg Lys Ala Gly Cys  
1 5 10 15

<210> 295  
<211> 16  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 295

Lys Ala Phe Ala Ala Leu Ala Ala Arg Leu Tyr Arg Lys Ala Gly Cys  
1 5 10 15

<210> 296  
<211> 16  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 296

Lys Ala Phe Ala Lys Leu Ala Ala Gln Leu Tyr Arg Lys Ala Gly Cys  
1 5 10 15

<210> 297  
<211> 15  
<212> PRT  
<213> Artificial Sequence  
  
<220>

<223> Derived sequence 03-228\_PCT.SeqListing1

<400> 297

Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
 1 5 10 15

<210> 298

<211> 160

<212> PRT

<213> Homo sapiens

<400> 298

Met Glu Ile Pro Val Pro Val Gln Pro Ser Trp Leu Arg Arg Ala Ser  
 1 5 10 15

Ala Pro Leu Pro Gly Leu Ser Ala Pro Gly Arg Leu Phe Asp Gln Arg  
 20 25 30

Phe Gly Glu Gly Leu Leu Glu Ala Glu Leu Ala Ala Leu Cys Pro Thr  
 35 40 45

Thr Leu Ala Pro Tyr Tyr Leu Arg Ala Pro Ser Val Ala Leu Pro Val  
 50 55 60

Ala Gln Val Pro Thr Asp Pro Gly His Phe Ser Val Leu Leu Asp Val  
 65 70 75 80

Lys His Phe Ser Pro Glu Glu Ile Ala Val Lys Val Val Gly Glu His  
 85 90 95

Val Glu Val His Ala Arg His Glu Glu Arg Pro Asp Glu His Gly Phe  
 100 105 110

Val Ala Arg Glu Phe His Arg Arg Tyr Arg Leu Pro Pro Gly Val Asp  
 115 120 125

Pro Ala Ala Val Thr Ser Ala Leu Ser Pro Glu Gly Val Leu Ser Ile  
 130 135 140

Gln Ala Ala Pro Ala Ser Ala Gln Ala Pro Pro Pro Ala Ala Ala Lys  
 145 150 155 160

<210> 299

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Derived sequence

<400> 299

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
 1 5 10

## 03-228\_PCT.SeqListing1

<210> 300  
<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (6)..(6)  
<223> Ser residue is phosphorylated.

<400> 300  
  
Trp Leu Arg Arg Ala Ser Ala Pro Leu Pro Gly Leu  
1 5 10

<210> 301  
<211> 23  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (17)..(17)  
<223> Ser residue is phosphorylated.

<400> 301  
  
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Trp Leu Arg Arg Ala  
1 5 10 15  
  
Ser Ala Pro Leu Pro Gly Leu  
20

<210> 302  
<211> 14  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<220>  
<221> misc\_feature  
<222> (3)..(3)  
<223> Ser residue is phosphorylated.

<400> 302  
  
Pro Arg Ser Leu Trp Ala Leu Gly Arg Pro Leu Ser Ala Lys  
1 5 10

<210> 303

03-228\_PCT.SeqListing1

<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 303

Ser Trp Leu Arg Arg  
1 5

<210> 304  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 304

Leu Arg Arg  
1

<210> 305  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 305

Pro Ser Trp Leu Arg Arg  
1 5

<210> 306  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 306

Asn Pro Ser Trp Leu Arg Arg  
1 5

<210> 307  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Derived sequence

<400> 307

Val Asn Pro Ser Trp Leu Arg Arg  
1 5

## 03-228\_PCT.SeqListing1

<210> 308  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 308

Pro Val Asn Pro Ser Trp Leu Arg Arg  
1 5

<210> 309  
<211> 10  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 309

Val Pro Val Asn Pro Ser Trp Leu Arg Arg  
1 5 10

<210> 310  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 310

Pro Val Pro Val Asn Pro Ser Trp Leu Arg Arg  
1 5 10

<210> 311  
<211> 13  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 311

Ile Pro Val Pro Pro Val Asn Pro Ser Trp Leu Arg Arg  
1 5 10

<210> 312  
<211> 14  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 312

## 03-228\_PCT.SeqListing1

Glu Ile Pro Val Pro Pro Val Asn Pro Ser Trp Leu Arg Arg  
1 5 10

<210> 313  
<211> 15  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 313

Met Glu Ile Pro Val Pro Pro Val Asn Pro Ser Trp Leu Arg Arg  
1 5 10 15

<210> 314  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived sequence  
  
<400> 314

Gly Leu Ser Ala Pro  
1 5

<210> 315  
<211> 23  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Derived Sequence  
  
<220>  
<221> misc\_feature  
<222> (17)..(17)  
<223> Ser residue is phosphorylated.

<400> 315

Tyr Ala Arg Ala Ala Ala Arg Gln Ala Arg Ala Trp Leu Arg Arg Ala  
1 5 10 15

Ser Ala Pro Leu Pro Gly Leu  
20

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US2004/004999A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K38/17 A61P17/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, BIOSIS, EMBASE, PASCAL, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 03/018758 A (KOMALAVILAS PADMINI ; BROPHY COLLEEN (US); LOKESH JOSHI (US); PANITCH) 6 March 2003 (2003-03-06) claims 1-72	1-23
P,A	TESSIER DERON J ET AL: "The small heat shock protein (HSP) 20 is dynamically associated with the actin cross-linking protein actinin." THE JOURNAL OF SURGICAL RESEARCH. 1 MAY 2003, vol. 111, no. 1, 1 May 2003 (2003-05-01), pages 152-157, XP001182463 ISSN: 0022-4804 the whole document	1-23

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the International search report

14 July 2004

22/07/2004

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fayos, C

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US2004/004999

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	<p>PARMITER CATHERINE MARGARET ET AL: "Protein transduction of biomimetic peptides leads to changes in the actin cytoskeleton of 3T3 cells." FASEB JOURNAL, vol. 17, no. 4-5, March 2003 (2003-03), pages Abstract No. 599.6 URL-<a href="http://www">http://www</a>, XP009033553</p> <p>&amp; FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; SAN DIEGO, CA, USA; APRIL 11-15, 2003 ISSN: 0892-6638 abstract</p> <p>-----</p> <p>BROPHY C M ET AL: "The small heat shock-related protein-20 is an actin-associated protein." JOURNAL OF VASCULAR SURGERY : OFFICIAL PUBLICATION, THE SOCIETY FOR VASCULAR SURGERY 'AND! INTERNATIONAL SOCIETY FOR CARDIOVASCULAR SURGERY, NORTH AMERICAN CHAPTER. FEB 1999, vol. 29, no. 2, February 1999 (1999-02), pages 326-333, XP009033572 ISSN: 0741-5214 the whole document</p> <p>-----</p>	1-23
A		1-23

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2004/004999

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US2004/004999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03018758	A 06-03-2003	CA 2458574 A1	06-03-2003
		WO 03018758 A2	06-03-2003
		US 2003060399 A1	27-03-2003